PIA
LFCR icon

Piedmont Investment Advisors’s Lifecore Biomedical LFCR Stock Holding History

Piedmont Investment Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-471
Closed -$7K – 1717
2018
Q2 		$7K Buy
+471
New +$6.54K ﹤0.01% 1976

Other funds holding LFCR

NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Piedmont Investment Advisors's LFCR Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Lifecore Biomedical (LFCR) in Q3 2018, closing a stake of 471 shares — an estimated $7K sold.

Piedmont Investment Advisors first reported a position in LFCR in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 90 funds tracked by Wall St. Rank hold LFCR as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Lifecore Biomedical position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 471 Lifecore Biomedical shares in Q3 2018, an estimated $7K.
  • Piedmont Investment Advisors first reported a position in Lifecore Biomedical in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Lifecore Biomedical position peaked at $7K in Q2 2018.
  • 90 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.